TNG456
Small molecule
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Glioblastoma · Phase 1/2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06810544 NCT06810544 · Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor, Non-Small Cell Adenocarcinoma, Lung Cancer, Brain Tumor Registry: NCT06810544 | 1/2 | Phase 1 Maximum Tolerated Dose (21 days); Phase 2 Anti-neoplastic Activity Single Agent (18 weeks); Phase 2 Anti-neoplastic Activity Combination Treatment (18 weeks) 2027-03-31 | In progress: results expected 31 Mar 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
Other PRMT5 drugs
AZD3470, BAY 3713372, Vopimetostat, HSK41959, IDE892. Compare all 6 PRMT5 drugs
6 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Glioblastoma: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| TNG456: this drug | Phase 1/2 | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary in this indication | |
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Temozolomide | Approved | Small molecule | DNA alkylation (O6-guanine) | not yet graded | No reviewed efficacy summary in this indication | |
| Niraparib | Phase 3 | Small molecule | PARP1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD3470 | Phase 1/2(overall) | Small molecule | PRMT5 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Temferon | Phase 1/2 | Gene therapy / editing | Interferon-alpha2 (myeloid-specific expression), Interferon-alpha2 (IFN-alpha2) expression in myeloid cells | not yet graded | No reviewed efficacy summary in this indication | |
| Zedoresertib | Phase 1/2 | Small molecule | WEE1 kinase | not yet graded | No reviewed efficacy summary in this indication | |
| AZD1390 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Ralometostat | Discontinued | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow TNG456 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.